Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Jurnal Ekonomi

Analysis Of The Effectiveness Of LMWH Compared To UFH In COVID-19 Patients With Coagulation Disorders At Pasar Minggu Regional General Hospital Edwina Dharmawati; Yusi Anggriani; Muhammad Reza
Jurnal Ekonomi Vol. 13 No. 04 (2024): Edition October -December 2024
Publisher : SEAN Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: COVID-19 disease causes multiorgan damage and impacts the cardiovascular system. The Increase in death cases occurs due to coagulation disorders characterized by increased d-dimer parameters, bleeding, thrombocytopenia, and thrombosis. Objective: To analyze the effectiveness of the use of LMWH anticoagulants compared to UFH in COVID-19 patients with coagulation disorders in hospital. Methods: Observational retrospective data collected1with cross sectional design. Methods of collecting data on COVID-19 inpatients in the January-December 2021 period based on moderate, severe, and critical severity of the disease. The data used is medical record data and analysis using chi square. Results: The sample consisted of 6362patients who met the inclusion criteria with the largest difference in decrease D-dimer values in critical severity for LMWH (4.8 ug/ml) and UFH (4.0 ug/ml). Wilcoxon test analysis *showed that there was a significant difference between the use of LMWH and UFH based on the decrease in D-dimer values.
Analysis Of Risk Factors For Acute Kidney Injury (AKI) With The Use Of Favipiravir And Remdesivir In Covid-19 Patients At Fatmawati Central General Hospital Nurlela Nurlela; Hesty Utami Ramadaniati; Yusi Anggriani; Ahmad Subhan
Jurnal Ekonomi Vol. 13 No. 02 (2024): Jurnal Ekonomi, Edition April - June 2024
Publisher : SEAN Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

COVID-19 patients are very vulnerable to complications of Acute Kidney Injury (AKI), there are many factors causing complications one of which is kidney toxic therapy, antiviral therapy is considered potentially toxic to the kidneys because most of it is excreted through the kidneys. This study was conducted to examine the risk factor profile of AKI in COVID-19 patients taking antivirals Remdesivir and Favipiravir. This study is an observational study with a cross-sectional design at Fatmawati Hospital. The sampling method uses total sampling during the period August 2020-July 2021. The data used is medical record. Bivariate analysis uses Chi-square, and multivariate analysis uses logistic regression. a sample of 208 patients who met the inclusion criteria in the period August 2020-July 2021 in the COVID-19 isolation room of Fatmawati Hospital. 135 patients using Favipiravir, 37 identified as having an AKI event and 73 patients using Remdesivir, 19 were identified as having an AKI event. Multivariate analysis with logistic regression showed that male sex and severity of severe to critical severity significantly influenced the incidence of AKI. The use of Favipiravir and Remdesivir in COVID-19 patients is not a risk factor for AKI.